Moderna, trailing rivals, checks its RSV shot expectations

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Delilah Alvarado Member since October 31, 2023

Loading + Follow Following